QP Current Practices Challenges and Mysteries_Almac_March2012

More documents

Recommendations

Info

ContinuedLicensed Drug Products– Does the CTA take into account anymodification in relation to the MA or equivalent?– Are NIMPs in the study truly NIMPs?– Is the Drug Product the same as that detailed inthe CTA?– Is the expiry date the same or less than theexpiry date of the licensed lot?– Be wary of counterfeit material?
Common pitfalls- Shelf life detailed in IMPD not reflected indrug product labelling- Regulatory Authorities or <strong>QP</strong> not informed ofchanges- Critical path- may result in delay in <strong>QP</strong>Release!
Page 2 and 3: Agenda• QP Roles and Responsibili
Page 4 and 5: QP Roles andResponsibilities• IMP
Page 6: QP RELEASE PROCESS1. SupplyChainVer
Page 10 and 11: Sites to be verified• Biological
Page 12 and 13: Sites to be verified• Drug produc
Page 14 and 15: Continued…• Who can confirm EU
Page 16 and 17: QP Declaration• May be confused w
Page 18 and 19: Common Pitfalls• All sites used i
Page 20 and 21: Common Pitfalls• Site address or
Page 22 and 23: Study SpecificDocumentation• Reme
Page 24 and 25: Continued…• Document of greates
Page 26 and 27: Continued…Contains or makes refer
Page 28 and 29: QP RELEASE PROCESS3. LotSpecificInf
Page 30 and 31: Documentation requiredFor Drug Subs
Page 32 and 33: Continued…• Biological Drug Sub
Page 34 and 35: Continued…• Memo to confirm the
Page 36 and 37: Continued• Non- EU Licensed Drug
Page 40 and 41: QP release• Remember QP Legal Dut
Page 42 and 43: Updates• QP Facilitation Programm
Page 44 and 45: Continued…• Common goal for bot
Page 46: Summary• QP Roles and Responsibil

QP Current Practices Challenges and Mysteries_Almac_March2012

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?